These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 31096160)

  • 1. Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma.
    Vizcaino MA; Giannini C; Vaubel RA; Nguyen AT; Trejo-Lopez JA; Raghunathan A; Jenkins SM; Jenkins RB; Zepeda Mendoza CJ
    J Neuropathol Exp Neurol; 2024 Jul; ():. PubMed ID: 39042515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MTAP-CDKN2A locus confers susceptibility to a naturally occurring canine cancer.
    Shearin AL; Hedan B; Cadieu E; Erich SA; Schmidt EV; Faden DL; Cullen J; Abadie J; Kwon EM; Gröne A; Devauchelle P; Rimbault M; Karyadi DM; Lynch M; Galibert F; Breen M; Rutteman GR; André C; Parker HG; Ostrander EA
    Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1019-27. PubMed ID: 22623710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the absence: homozygous DNA deletions as immutable signposts for cancer therapy.
    Varshavsky A
    Proc Natl Acad Sci U S A; 2007 Sep; 104(38):14935-40. PubMed ID: 17846424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-resolution analysis of aberrant regions in autosomal chromosomes in human leukemia THP-1 cell line.
    Adati N; Huang MC; Suzuki T; Suzuki H; Kojima T
    BMC Res Notes; 2009 Jul; 2():153. PubMed ID: 19635138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletions of DNA in cancer and their possible uses for therapy.
    Varshavsky A; Lewis K; Chen SJ
    Bioessays; 2023 Jul; 45(7):e2300051. PubMed ID: 37166062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
    Hamid AB; Petreaca RC
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32283832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial: Methods in cancer genetics.
    D'Aguanno S; Buczkowicz P
    Front Oncol; 2023; 13():1227854. PubMed ID: 37469406
    [No Abstract]   [Full Text] [Related]  

  • 9. Distribution of copy number variations and rearrangement endpoints in human cancers with a review of literature.
    Mirzaei G; Petreaca RC
    Mutat Res; 2022; 824():111773. PubMed ID: 35091282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusion transcripts and their genomic breakpoints in polyadenylated and ribosomal RNA-minus RNA sequencing data.
    Hoogstrate Y; Komor MA; Böttcher R; van Riet J; van de Werken HJG; van Lieshout S; Hoffmann R; van den Broek E; Bolijn AS; Dits N; Sie D; van der Meer D; Pepers F; Bangma CH; van Leenders GJLH; Smid M; French PJ; Martens JWM; van Workum W; van der Spek PJ; Janssen B; Caldenhoven E; Rausch C; de Jong M; Stubbs AP; Meijer GA; Fijneman RJA; Jenster GW
    Gigascience; 2021 Dec; 10(12):. PubMed ID: 34891161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
    Funakoshi Y; Hata N; Takigawa K; Arita H; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Sako A; Umehara T; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iwaki T; Mizoguchi M
    Cancer Med; 2021 May; 10(10):3177-3187. PubMed ID: 33838014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology.
    Zeng J; Johnson A; Shufean MA; Kahle M; Yang D; Woodman SE; Vu T; Moorthy S; Holla V; Meric-Bernstam F
    JCO Clin Cancer Inform; 2019 Sep; 3():1-12. PubMed ID: 31550176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of CDKN2A(p16)/CDKN2B(p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma.
    Hamada K; Kohno T; Kawanishi M; Ohwada S; Yokota J
    Genes Chromosomes Cancer; 1998 Jul; 22(3):232-40. PubMed ID: 9624535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.
    Stadler WM; Olopade OI
    Urol Res; 1996; 24(4):239-44. PubMed ID: 8873383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines.
    Raschke S; Balz V; Efferth T; Schulz WA; Florl AR
    Genes Chromosomes Cancer; 2005 Jan; 42(1):58-67. PubMed ID: 15495191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
    Pollock PM; Pearson JV; Hayward NK
    Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
    Walker GJ; Flores JF; Glendening JM; Lin AH; Markl ID; Fountain JW
    Genes Chromosomes Cancer; 1998 Jun; 22(2):157-63. PubMed ID: 9598804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent homozygous deletions of the CDKN2A locus in somatic cancer tissues.
    Hamid A; Petreaca B; Petreaca R
    Mutat Res; 2019 May; 815():30-40. PubMed ID: 31096160
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.